South Africa: Changes to ART guidelines

All HIV-positive TB patients, with immediate effect, are initiated on ART, irrespective of CD4 count.

Read More →

TB CAB: Open letters to drug companies and FDA on delanamid and bedaquiline

Open letters to Otsuka, Janssen Pharmaceutical Companies of Johnson & Johnson, Food and Drug Administration and European Medicines Agency.

Read More →

MSF: Opportunity to transform medical innovation before health ministers

Medical innovation is not delivering for the needs of people in developing countries. 65th World Health Assembly to debate binding convention on R&D.

Read More →

Scaling up interventions to achieve global tuberculosis control: progress and new developments

Tuberculosis is still one of the most important causes of death worldwide. Perseverance and renewed commitment are needed to achieve global control of tuberculosis, and ultimately, its elimination.

Read More →

Report: GeneXpert TB diagnostics take off in low-resource countries

As of the end of the first quarter of 2012, nearly 864,000 GeneXpert MTB/RIF rapid tuberculosis (TB) diagnostic cartridges had been procured under manufacturer Cephied’s concessional pricing mechanism.

Read More →

USAID: “Global health and child survival: Progress report to Congress 2010-2011”

Between 1990 and 2010, in countries with tuberculosis (TB) programs supported by USAID, TB death rates decreased by 29 percent, and TB prevalence rates declined by 14 percent.

Read More →

UNITAID: Release of latest progress report “Five years of innovation for better health”

Through spearheading innovative initiatives and providing financing for global health over the past five years, UNITAID has had a dramatic impact on millions of lives, using creative market approaches to increase access to treatment and diagnostics for HIV, malaria and tuberculosis.

Read More →

Response by Medicines Control Council

Response by Medicines Control Council to letter by Global TB CAB on bedaquiline.

Read More →

TB identified as a top priority in fighting the biggest killer diseases

Research released by the Copenhagen Consensus Center identifies TB as a key priority for infectious disease control in terms of cost effectiveness and disease burden.

Read More →

TB CAB: Open letter

Open letter regarding Cepheid pricing of the GeneXpert machines and cartridges for high-burden settings in the public and private sectors.

Read More →

Page 82 of 90 · Total posts: 10

←First 81 82 83 Last→